bcbs michigan glp 1 Blue Cross Blue Shield of won't cover popular weight-loss drugs Blue Cross Blue Shield of
Description
In partnership with KFF Health News, NBCs Anne Thompson reports for TODAY.
Novo Nordisk is seeking to replace the existing glucagon-like peptide-1 (GLP-1) receptor agonist (RA) with a second-generation drug, semaglutide, to fight diabetes and obesity in Korea.On Thursday, the Ministry of Food and Drug Safety authorized the use of Novo Nordisks Ozempic to treat adults with
Recent studies report visual side effects, which have the eye care world wondering if GLP-1s are a little too good to be true.
Doctors and groups representing employers said theyre increasingly hearing about companies cutting weight loss drugs out of health plans next year.
